CN107001372B - 取代的氨基嘌呤化合物、其组合物及其治疗方法 - Google Patents

取代的氨基嘌呤化合物、其组合物及其治疗方法 Download PDF

Info

Publication number: CN107001372B
Authority: CN; China
Prior art keywords: purin; cyclohexanecarboxamide; ylamino; chloro; dichloro
Prior art date: 2014-10-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201580065272.2A

Other languages

English (en)

Chinese (zh)

Other versions

CN107001372A (zh

Inventor

马修·亚历山大

索哥利·巴曼亚

约翰·弗雷德里克·博伊兰

约书亚·汉森

黄德华

罗伯特·哈伯德

布兰登·杰菲

吉姆·莱斯滕

迈赫兰·穆贾达姆

拉杰·K·拉赫加

希瑟·雷蒙

金佰利·施华兹

玛丽安·斯洛斯

艾杜亚度·托里斯

塔姆·明·特朗

徐水蟾

赵晶晶

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Signal Pharmaceuticals LLC

Original Assignee

Signal Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-06

Filing date

2015-10-05

Publication date

2021-04-27

2015-10-05 Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC

2015-10-05 Priority to CN202110381676.XA priority Critical patent/CN113248506A/zh

2017-08-01 Publication of CN107001372A publication Critical patent/CN107001372A/zh

2021-04-27 Application granted granted Critical

2021-04-27 Publication of CN107001372B publication Critical patent/CN107001372B/zh

Status Active legal-status Critical Current

2035-10-05 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CN201580065272.2A 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法 Active CN107001372B (zh)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CN202110381676.XA CN113248506A (zh)	2014-10-06	2015-10-05	取代的氨基嘌呤化合物、其组合物及其治疗方法

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462060339P	2014-10-06	2014-10-06
US62/060,339		2014-10-06
PCT/US2015/053941 WO2016057370A1 (en)	2014-10-06	2015-10-05	Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CN202110381676.XA Division CN113248506A (zh)	2014-10-06	2015-10-05	取代的氨基嘌呤化合物、其组合物及其治疗方法

Publications (2)

Publication Number	Publication Date
CN107001372A CN107001372A (zh)	2017-08-01
CN107001372B true CN107001372B (zh)	2021-04-27

Family

ID=55632334

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201580065272.2A Active CN107001372B (zh)	2014-10-06	2015-10-05	取代的氨基嘌呤化合物、其组合物及其治疗方法
CN202110381676.XA Pending CN113248506A (zh)	2014-10-06	2015-10-05	取代的氨基嘌呤化合物、其组合物及其治疗方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN202110381676.XA Pending CN113248506A (zh)	2014-10-06	2015-10-05	取代的氨基嘌呤化合物、其组合物及其治疗方法

Country Status (28)

Country	Link
US (8)	US9512124B2 (2)
EP (2)	EP3204386B1 (2)
JP (4)	JP6884701B2 (2)
KR (2)	KR20230035424A (2)
CN (2)	CN107001372B (2)
AR (2)	AR102171A1 (2)
AU (2)	AU2015328414B2 (2)
CA (1)	CA2963639C (2)
CL (1)	CL2017000820A1 (2)
CO (1)	CO2017003838A2 (2)
CY (1)	CY1124173T1 (2)
DK (1)	DK3204386T3 (2)
EA (1)	EA201790779A1 (2)
EC (1)	ECSP17026210A (2)
ES (2)	ES2980464T3 (2)
HR (1)	HRP20210656T1 (2)
HU (1)	HUE054694T2 (2)
IL (2)	IL251566B (2)
LT (1)	LT3204386T (2)
MX (2)	MX388321B (2)
PL (1)	PL3204386T3 (2)
PT (1)	PT3204386T (2)
RS (1)	RS61884B1 (2)
SG (2)	SG11201702759XA (2)
SI (1)	SI3204386T1 (2)
SM (1)	SMT202100302T1 (2)
TW (1)	TW201629063A (2)
WO (1)	WO2016057370A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9512124B2 (en)	2014-10-06	2016-12-06	Signal Pharmaceuticals, Llc	Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
US9513297B2 (en)	2014-12-16	2016-12-06	Signal Pharmaceuticals, Llc	Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (en)	2015-01-29	2024-11-20	Signal Pharmaceuticals, LLC	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2982446A1 (en)	2015-03-18	2016-09-22	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds useful as inhibitors of tnf
MX2017011577A (es)	2015-03-18	2017-10-26	Bristol Myers Squibb Co	Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
AU2016233288A1 (en)	2015-03-18	2017-11-09	Bristol-Myers Squibb Company	Substituted tricyclic heterocyclic compounds
CN107922287B (zh)	2015-07-24	2021-04-09	细胞基因公司	合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
KR102679517B1 (ko)	2015-08-03	2024-06-27	브리스톨-마이어스 스큅 컴퍼니	Tnf 알파의 조정제로서 유용한 시클릭 화합물
MX379513B (es) *	2016-04-01	2025-03-11	Signal Pharm Llc	Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.
HUE056631T2 (hu) *	2016-04-01	2022-02-28	Signal Pharm Llc	(1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik
EP3464312A4 (en)	2016-06-02	2019-11-27	Celgene Corporation	ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
JP6970126B2 (ja) *	2016-06-02	2021-11-24	セルジーンコーポレイション	動物及びヒトの抗マラリア薬
CN111417634A (zh) *	2017-10-04	2020-07-14	细胞基因公司	用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
AU2018345647A1 (en)	2017-10-04	2020-04-16	Celgene Corporation	Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
TW202202498A (zh) *	2020-07-01	2022-01-16	大陸商四川海思科製藥有限公司	一種並環雜環衍生物及其在醫藥上的應用
US12084453B2 (en)	2021-12-10	2024-09-10	Incyte Corporation	Bicyclic amines as CDK12 inhibitors
CN114478326B (zh) *	2022-01-21	2023-10-03	安徽宁亿泰科技有限公司	一种苯嘧磺草胺关键中间体的合成方法
CN117964497B (zh) *	2024-01-26	2026-03-31	江西凯信生物医药有限公司	一种3,3-二氟环戊胺盐酸盐的合成方法
CN121758295A (zh) *	2024-09-30	2026-03-31	青岛清原化合物有限公司	一种亚氨基芳基类化合物及中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103087066A (zh) *	2005-01-13	2013-05-08	西格诺药品有限公司	卤代芳基取代的氨基嘌呤、其组合物及其治疗方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi)	1997-09-19	2002-05-31	Leiras Oy	Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) *	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) *	2004-07-19	2010-03-02	Resonant Medical, Inc.	Weighted surface-to-surface mapping
US7521446B2 (en)	2005-01-13	2009-04-21	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en)	2005-01-13	2010-07-20	Signal Pharmaceuticals, Llc	Methods of treatment and prevention using haloaryl substituted aminopurines
WO2007062338A2 (en)	2005-11-18	2007-05-31	Astrazeneca Ab	Solid formulations
TWI398252B (zh)	2006-05-26	2013-06-11	諾華公司	吡咯并嘧啶化合物及其用途
CA2667345C (en)	2006-10-27	2016-03-22	Signal Pharmaceuticals, Llc	Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
ES2400006T3 (es)	2008-04-23	2013-04-04	Farmasierra Manufacturing, S.L.	Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en)	2009-12-09	2011-06-16	Signal Pharmaceuticals, Llc	Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en)	2010-10-25	2013-12-10	Signal Pharmaceuticals, Llc	Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) *	2010-10-25	2014-03-25	Signal Pharmaceuticals, Llc	Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US20160082015A1 (en)	2013-04-18	2016-03-24	President And Fellows Of Harvard College	Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en)	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic Agents
US9512124B2 (en)	2014-10-06	2016-12-06	Signal Pharmaceuticals, Llc	Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
HUE056631T2 (hu)	2016-04-01	2022-02-28	Signal Pharm Llc	(1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik

2015
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
2017
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103087066A (zh) *	2005-01-13	2013-05-08	西格诺药品有限公司	卤代芳基取代的氨基嘌呤、其组合物及其治疗方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor;Plantevin Krenitsky et al.;《Bioorganic & Medicinal Chemistry Letters》;20121231;第22卷(第3期);第1433-1438页 *

Also Published As

Publication number	Publication date
HUE054694T2 (hu)	2021-09-28
SMT202100302T1 (it)	2021-07-12
ES2980464T3 (es)	2024-10-01
IL277069A (en)	2020-10-29
US20170042902A1 (en)	2017-02-16
US11590139B2 (en)	2023-02-28
AU2015328414B2 (en)	2020-03-19
ECSP17026210A (es)	2017-05-31
CL2017000820A1 (es)	2017-12-15
EP3204386A4 (en)	2018-04-18
CA2963639A1 (en)	2016-04-14
US9737541B2 (en)	2017-08-22
IL251566B (en)	2020-09-30
NZ730753A (en)	2024-02-23
BR112017006998A2 (pt)	2018-01-16
SI3204386T1 (sl)	2021-08-31
JP7196270B2 (ja)	2022-12-26
EP3822274A1 (en)	2021-05-19
DK3204386T3 (da)	2021-05-25
EP3822274B1 (en)	2024-03-06
US10398700B2 (en)	2019-09-03
JP2020033352A (ja)	2020-03-05
US10940152B2 (en)	2021-03-09
US20190091230A1 (en)	2019-03-28
AR102171A1 (es)	2017-02-08
SG10202009598VA (en)	2020-10-29
NZ767954A (en)	2024-02-23
US10646493B2 (en)	2020-05-12
RS61884B1 (sr)	2021-06-30
MX2017004600A (es)	2017-06-30
CY1124173T1 (el)	2022-05-27
CA2963639C (en)	2023-07-04
LT3204386T (lt)	2021-07-12
CO2017003838A2 (es)	2017-07-11
JP6987823B2 (ja)	2022-01-05
JP2017530199A (ja)	2017-10-12
EP3204386A1 (en)	2017-08-16
AU2020201486A1 (en)	2020-03-19
US20170296546A1 (en)	2017-10-19
TW201629063A (zh)	2016-08-16
AR128748A2 (es)	2024-06-12
US10149849B2 (en)	2018-12-11
IL277069B (en)	2022-05-01
JP6884701B2 (ja)	2021-06-09
JP2023027269A (ja)	2023-03-01
AU2015328414A1 (en)	2017-04-27
JP2022033858A (ja)	2022-03-02
KR20170063740A (ko)	2017-06-08
SG11201702759XA (en)	2017-05-30
MX388321B (es)	2025-03-19
AU2020201486B2 (en)	2021-07-08
US20230158035A1 (en)	2023-05-25
US20160096841A1 (en)	2016-04-07
US20210128565A1 (en)	2021-05-06
WO2016057370A1 (en)	2016-04-14
CN107001372A (zh)	2017-08-01
HRP20210656T1 (hr)	2021-07-23
US20190336507A1 (en)	2019-11-07
MX2021014531A (es)	2022-01-06
KR102504849B1 (ko)	2023-03-02
ES2871142T3 (es)	2021-10-28
CN113248506A (zh)	2021-08-13
PL3204386T3 (pl)	2021-09-20
KR20230035424A (ko)	2023-03-13
US9512124B2 (en)	2016-12-06
IL251566A0 (en)	2017-05-29
PT3204386T (pt)	2021-05-31
US20200237768A1 (en)	2020-07-30
EA201790779A1 (ru)	2017-09-29
EP3204386B1 (en)	2021-03-03

Legal Events

Date	Code	Title
2017-08-01	PB01	Publication
2017-08-01	PB01	Publication
2017-10-31	SE01	Entry into force of request for substantive examination
2017-10-31	SE01	Entry into force of request for substantive examination
2021-04-27	GR01	Patent grant
2021-04-27	GR01	Patent grant

Publication	Publication Date	Title
CN107001372B (zh)	2021-04-27	取代的氨基嘌呤化合物、其组合物及其治疗方法
US20230116093A1 (en)	2023-04-13	Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EA031671B1 (ru)	2019-02-28	Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения
HK1241852B (en)	2021-10-22	Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
BR112017006998B1 (pt)	2023-09-19	Composto de aminopurina substituído, composição farmacêutica compreendendo o mesmo, uso e método para preparar o referido composto e métodos in vitro e ex vivo de inibição de quinase
AU2015201030B2 (en)	2016-09-29	Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith